Regeneron Pharmaceuticals, Inc. (REGN) has seen some recent movement in the market and its common shares closed at $553.50 yesterday. Investors are starting to take notice of REGN as the common shares traded as high as $569.99 and as low as $541.68 in the previous market day.

Regeneron Pharmaceuticals, Inc. (REGN) average trading volume is 1.39M. However, in the previous market day Regeneron Pharmaceuticals, Inc. (REGN) traded 1,905,107 shares. The first support level on REGN is $541.56 and the first resistance level on REGN is $605.92. REGN 50-day moving average is $509.92 and REGN two hundred day moving average is $410.05.

Regeneron Pharmaceuticals, Inc. (REGN) recent performance has been specified by the recent movement in REGN common shares. REGN has performed 9.76% over the past 30 days, REGN has performed 48.73% over the past 3 months and REGN has shown 71.68% over the past 365 days. Regeneron Pharmaceuticals, Inc. (REGN) has a 12 month range of $271.37 to $581.00. Regeneron Pharmaceuticals, Inc. (REGN) is trading 103.97% from its 12 month low and -4.73% from its 12 month high. Regeneron Pharmaceuticals, Inc. (REGN) is displaying a 2.46% short float displaying the amount short in the float.

REGN has 110.10M shares outstanding and 81.81M shares in the float. Regeneron Pharmaceuticals, Inc. (REGN) at this time has a market cap of $60.94B and income of $2.12B. The EPS next quarter for REGN is 6.13 and forecasted EPS net year is 16.65%. The market cap of Regeneron Pharmaceuticals, Inc. (REGN) at $60.94B signifies how many Investors own shares of REGN and is calculated off the last price ($553.50) of REGN and the amount of shares outstanding (110.10M) with Regeneron Pharmaceuticals, Inc. (REGN).

Regeneron Pharmaceuticals, Inc. (REGN) has total cash (mrq) of 4B, total cash per share (mrq) of 36.78, total debt of REGN is at 715.2M and total debt/equity (mrq) is 5.89. Regeneron Pharmaceuticals, Inc. (REGN) running cash flow (ttm) is 2.23B and REGN leveraged free cash flow (ttm) is 1.28B.

REGN is trading 2.97% above (bullish) its SMA20, 11.69% above (bullish) its SMA50 and 48.52% above (bullish) its SMA200.

Recent News:

In recent news, on May 5, 2020, it was announced, Regeneron Reports First Quarter 2020 Financial and Operating Results. In this news it stated, TARRYTOWN, N.Y. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2020 and provided a business update.

About Regeneron Pharmaceuticals, Inc. (REGN):

Tarrytown, NY-based Regeneron is a biopharmaceutical company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company’s portfolio boasts about seven marketed drugs — Eylea (for several eye diseases), Dupixent (asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis), Praluent (heterozygous familial hypercholesterolemia), Kevzara (moderately-to-severely active rheumatoid arthritis), Libtayo (metastatic or locally advanced cutaneous squamous cell carcinoma), Arcalyst and Zaltrap. While Regeneron has co-developed Eylea with Bayer’s HealthCare unit, Praluent was co-developed with Sanofi.